Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway

Kosuke Ogawa1†, Qiushi Lin2†, Xuewei Bai1,3, Xuesong Chen4, Hua Chen3, Rui Kong3, Yongwei Wang3, Hong Zhu5, Fuliang He2,6, Qinggang Xu2,7, Lianxin Liu3,9, Min Li10, Songhua Zhang1, Katsuya Nagaoka1, Rolf Carlson1, Howard Safran11, Kevin Charpentier12, Bei Sun3, Jack Wands1* and Xiaoqun Dong1,2,13*

Abstract

Background: Signaling pathways critical for embryonic development re-emerge in adult pancreas during tumorigenesis. Aspartate β-hydroxylase (ASPH) drives embryonic cell motility/invasion in pancreatic development/differentiation. We explored if dysregulated ASPH is critically involved in pancreatic cancer pathogenesis.

Methods: To demonstrate if/how ASPH mediates malignant phenotypes, proliferation, migration, 2-D/3-D invasion, pancreatosphere formation, immunofluorescence, Western blot, co-immunoprecipitation, invadopodia formation/maturation/function, qRT-PCR, immunohistochemistry (IHC), and self-developed in vitro metastasis assays were performed. Patient-derived xenograft (PDX) models of human pancreatic ductal adenocarcinoma (PDAC) were established to illustrate in vivo antitumor effects of the third-generation small molecule inhibitor specifically against ASPH’s β-hydroxylase activity. Prognostic values of ASPH network components were evaluated with Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models.

(Continued on next page)
Background

Pancreatic cancer is an intractable malignancy, with 458,918 new cases and 432,242 deaths globally in 2018 [1]. Pancreatic cancer ranks the fourth-leading cause of cancer deaths in the USA, with an estimated of 56,770 new cases and 45,750 deaths in 2019 [2]. Pancreatic cancer has a dismal prognosis; after diagnosis, 25% of patients survive 1 year; only 5–8% survive 5 years. More than 85% of pancreatic cancer is classified as pancreatic ductal adenocarcinoma (PDAC), which is originated from the exocrine glands. Pancreatic cancer is usually symptom-free at the early stage, with gradual progression, and nonspecifically manifests as fatigue, abdominal pain, weight loss, light-colored stools, and jaundice [2]. With disease progression, vast majority of PDAC patients develop relapsed/metastatic tumors invading into the liver, (retro) peritoneal organs, colon, rectum, and lungs. The silent nature, multiple-drug resistance, rapid recurrence, and lack of early detection approaches necessitate active exploration of molecular mechanisms responsible for pancreatic tumorigenesis, progression, and metastasis, so that optimal targets for comprehensive therapy can be identified. We have identified ASPH with potential for achieving this goal. ASPH is a type II transmembrane hydroxylase and a member of highly conserved α-ketoglutarate-dependent hydroxylase (a superfamily non-heme iron-containing protein). The aspartyl and asparaginyl residues in EGF-like repeats of various proteins are natural substrates of ASPH. The embryonic pancreas has been shown to share common signaling pathways with the adult pancreas during malignant transformation. ASPH is a potential driving factor for cell motility and invasion in pancreatic development/differentiation in the embryo [3] and promotes oncogenesis in the adult. ASPH is upregulated by RAS/RAF/ MAPK/ERK, PI3K/AKT, and WNT/β-catenin [4–8] to initiate tumorigenesis [4, 9]. However, how ASPH regulates downstream effectors as a determinant for aggressive/invasive phenotypes of pancreatic cancer cells remains mysterious.

Intravasation/extravasation are critical steps for tumor cells to metastasize, however, precise mechanisms regulating these dynamic processes are yet to be clarified. Invadopodia are actin-rich protrusive structures of the plasma membrane to degrade the extracellular matrix (ECM), as a key step for cancer invasion and metastasis. Extending between endothelial cells, intravascular cancer cells “sprout” protrusions [10]. Invadopodia enable the aggressive tumor cells to invade through ECM, intravasate, and extravasate. Invadopodia are composed of structural proteins (e.g., Neural Wiskott-Aldrich syndrome protein (N-WASP), Arp2/3 complex, LIM-kinase, cofillin, cortactin (especially for initiation), Tks5 (important for formation and maturation) and Tks4 (in particular for function) [10]) and ECM-degrading effectors (e.g., MMP14/MT1-MMP, MMP2/9 for locally directed release [11]). Invadopodia can be identified in vivo based on the localization of cortactin, Tks4/ Tks5 and MT1-MMP [10]. However, whether invadopodia play a role in ASPH-induced aggressive malignant phenotypes of pancreatic cancer has yet to be disclosed.
Methods

Cell lines
Human umbilical vein/vascular endothelium (HUVEC) and pancreatic cancer cell lines were purchased from American type culture collection and authenticated by short tandem repeat profiling to reduce misidentification. HUVECs were grown in complete F-12 K medium and used at passages 5–10. Cancer cells were passaged at 80% of confluence. Stable MIA-Paca2 cell lines over-expressing empty vector and ASPH were established using a lentiviral system (GeneCopoeia, #EX-Z8758-Lv105), whereas stable AsPC-1 and HPAFII cell lines that express CRISPR vector and Cas9-guide RNA (gRNA) specific to ASPH were established using the CRISPR-CAS9 system. All stable cell lines expressing GFP were generated for in vitro metastasis assays.

Plasmids and reagents
Plasmids P lent-CMV-ASPH-Lv105 (EX-Z8758-Lv105) and P lent-CMV-Lv105 empty vector were purchased from GeneCopoeia; pLenti-CMV-GFP-Hygro (656-4) and p lentCRISPR v2 from Addgene (Cambridge, MA); and pRP-Hygro-CMV-ADAM12 and pRP-Hygro-CMV-ADAM15 from Vectorbuild. Dasatinib (CDS023389-25MG) and Wiskostatin (W2270-5MG) were purchased from Sigma-Aldrich and examined at multiple concentrations within an effective range and with minimal off-target effects or toxicity.

Western Blot
Cell lysates (20–40 μg) were separated by SDS-PAGE and transferred to nitrocellulose membranes using primary antibodies for ASPH (FB50, homemade); MMP14 (#13130S), SRC (#2109S), SRCY16 (#6943S), SRCY527 (#2105S), FAK (#13009S), Phospho-FAK Tyr397 (#8556S), FAK Tyr566/567 (#3281S), FAK Tyr925 (#3284S), and Alexa Fluor® 488 Conjugate (#5198S) from BD Biosciences. The plate was incubated for 2 h at 37°C with corresponding serum-free medium. Immediately prior to the addition of dissociated cancer cells (2.5 × 10^4/500 μl) to the upper chamber, 750 μl of 10% FBS medium was added to the lower chamber. After incubated for 48–72 h, Matrigel and non-migrating cells were removed from the top chamber with Q-tips. Invading cells on the bottom were fixed in ethanol and stained with crystal violet. After drying overnight, stained cells were counted under a microscope. Percentage of invasion (invasion index) was calculated as a ratio of “Number of invaded cells through Matrigel insert membrane/Number of migrated cells through insert membrane in migration assay”. All data were obtained from ≥3 independent experiments.

Immunoprecipitation
HEK293 cells were cultured in 10-cm dishes and transfected with a total of 10 μg corresponding plasmids when reached 70% of confluence. Cells were harvested using 1 ml PBS containing 1% NP40.

Pancrasosphere formation
Matrigel (300 μl) was spread evenly to each well of a 24-well plate on ice. The plate was centrifuged at 4°C, 300g and immediately placed in a cell culture incubator for 30 min. Single cells were suspended in the medium with 10% Matrigel at a concentration of 2000/400 μl and seeded on Matrigel. Cells were allowed to attach to the Matrigel for 3 h. The medium was carefully removed and replaced with fresh medium containing 10% Matrigel. After incubated for 1 h, corresponding culture medium was added. Fresh medium containing 10% Matrigel was changed every 2 days. The spheres formed after 5–9 days were evaluated in terms of size and number by light microscopy. All experiments were performed in triplicate wells for each condition and repeated in triplicate.

Migration
Migration was assessed using 24-well Boyden chambers (BD Biosciences). The top chamber (Transwell) with 8.0-μm pores was inserted into a 24-well plate (bottom chamber). 1.2 ml 10% FBS containing medium was added in the bottom chamber as a chemoattractant. Cancer cells (2.5 × 10^5/well) were seeded onto the top chambers in 500 μl of corresponding serum-free mediums. After incubation for 48–72 h at 37°C, cancer cells on the top surface were mechanically removed with Q-tips, and migrated cells on the bottom surface were fixed and stained with crystal violet. The average number of migrated cells from 5 to 7 randomly chosen fields on the bottom surface was counted. All data were obtained from ≥3 independent experiments.

2-D invasion
Cancer cells growing in log phase were incubated in serum-free medium for 24 h. Matrigel invasion chambers (BD BioCoat Matrigel Invasion 24-well Chamber, 8 μm pores, BD Biosciences) were rehydrated for 2 h at 37°C with corresponding serum-free medium. Immediately prior to the addition of dissociated cancer cells (2.5 × 10^4/500 μl) to the upper chamber, 750 μl of 10% FBS medium was added to the lower chamber. After incubated for 48–72 h, Matrigel and non-migrating cells were removed from the top chamber with Q-tips. Invading cells on the bottom were fixed in ethanol and stained with crystal violet. After drying overnight, stained cells were counted under a microscope. Percentage of invasion (invasion index) was calculated as a ratio of “Number of invaded cells through Matrigel insert membrane/Number of migrated cells through insert membrane in migration assay”. All data were obtained from ≥3 independent experiments.
2% growth factor reduced Matrigel) of the respective cell line. A total of 400 μl was added to each well of a Matrigel pre-coated plate. The plate was incubated at 37 °C under 5% CO₂ for 5–7 days. To evaluate the effects of different pharmacologic inhibitors, each compound was added to the complete medium at the time of plating followed by fresh medium changes supplemented with each compound every day while growing the cells on growth factor reduced Matrigel. All experiments were performed in triplicate wells for each condition and repeated in triplicate.

**3D (spheroid) invasion**

To perform 3D Culture 96-Well BME Cell Invasion Assay (Trevenen Inc. Gaithersburg, MD), cancer cell monolayers were washed with PBS, dissociated by Trypsin, neutralized with complete growth medium. Cells were counted using a hemocytometer. Cell suspension was diluted to 1 × 10⁴ cells/ml (to obtain tumor spheroids of 300–500 μm in diameter 4 days after cell seeding). Cell suspension was dispensed into ULA 96-well round bottom plate and centrifuged at 200×g for 5 min. The plate was transferred to an incubator (37 °C, 5% CO₂, 95% humidity). After 3–5 days, spheroid formation was visually confirmed and proceeded with 3-D invasion assay. Basement membrane matrix was thawed on ice overnight. ULA 96-well plate containing 4-day-old spheroids was placed on ice. In total, 50 μl of basement membrane matrix was gently dispensed into each U-bottom well with six replicates in each group. The plate was centrifuged at 300×g for 3 min at 4 °C, then transferred to an incubator at 37 °C, allowing the basement membrane matrix to solidify. After 1 h, 100 μl/well of complete growth medium was gently added into each well. Invasion modulating agents were applied to the system to evaluate its respective impact on cellular phenotype. Spheroid invasion was visualized microscopically and quantitated with NIH IMAGEJ. All experiments were performed in triplicate wells for each condition and repeated in triplicate.

**Invadopodium formation and ECM degradation/remodeling**

Cover glass (18 mm; Fisher Scientific) was coated with pig skin green 488 conjugated Gelatin (G13186, Life Technologies). The gelatin was cross-linked with a 0.5% glutaraldehyde solution in a 12-well plate, followed by quenched with sodium borohydride (1 mg/ml) and washed three times with PBS. Pancreatic cancer cells (2 × 10⁶) were seeded to each well in 2 ml of complete medium. After 18–72 h, cells were fixed with 4% paraformaldehyde (PFA), permeabilized with 0.1% Triton X-100, blocked with 5% BSA, and probed for F-actin (Rhodamine phalloidin, R415, Life technologies). The coverslips were mounted over a glass slide with a drop of mounting medium containing DAPI. At least 15 fields per coverslip were imaged at all three channels (red, green, and blue) under × 40 magnification. To quantify invadopodia function, black and white images of gelatin degradation were analyzed using NIH IMAGEJ. The degraded area was normalized to the number of nuclei in the image from the same field. Modulating agents were applied to the system to evaluate its respective impact on cellular phenotype. All experiments were performed in triplicate wells for each condition and performed in triplicate.

**In vitro metastasis**

Matrigel invasion chambers (BD BioCoat Matrigel Invasion 24-well Chamber, 8 μm pores, BD Biosciences) were rehydrated for 2 h at 37 °C with serum-free medium. HUVECs (2 × 10⁵) in HUVEC medium were seeded in inserted chambers. After 24 h, lower chambers were coated with 290 μl of Matrigel and filled with 500 μl of HUVEC medium containing 10% FBS. Cancer cells (1–4 × 10⁵) stably expressing GFP in HUVEC medium (FBS-free) were plated onto a layer of HUVECs. The plate was incubated in CO₂ incubator for 3 days. Inserted 24-well chambers were removed, washed with PBS, and fixed with 4% PFA (Sigma-Aldrich) for 20 min, permeabilized with Triton X-100 for 20 min, and stained with phalloidin (red) and Hoechst. Transmigrated cancer cells passing through HUVECs were imaged using fluorescence microscope and counted. Cancer cells invaded into the Matrigel within the lower chambers were buried with corresponding medium containing 10% Matrigel, continuously cultured in complete growth medium for 7 days to allow pancreatosphere formation. Tumor spheres were imaged and evaluated in terms of size and number by fluorescence microscope.

**Establishment of PDX model**

**Patient’s tissue procurement**

Tumor tissues were collected from six patients (Additional file 7: Table S1) with primary PDAC who had undergone surgical resection. We randomly retrieved 10 surgically resected PDAC specimens from the de-identified archives at the Department of Pathology to illustrate the expression profiling of ASPH network. This study was approved by the Ethics Committee of Institutional Review Board (IRB) at Rhode Island Hospital/Brown University and conducted in accordance with all current ethical guidelines.

**Establishment of F1 generation PDX murine models**

PDAC tumor specimens were transferred to the animal procedure room within 0.5–1 h following surgical resection, washed by DMEM supplemented with 1% penicillin/streptomycin, and diced into several fragments (each
fragment with an estimated volume of \(5 \times 5 \times 5 \text{mm}^3\). Female (5- to 6-week-old; \(n = 6\)/group) NSG mice (Jackson Laboratory) were kept under pathogen-free conditions, fed standard chow, with free access to sterilized water. These animals were anesthetized with isoflurane (4% induction, 2% maintenance). A small incision was made on the lower back, and one to two tumor fragments were subcutaneously implanted. The residual tumor fragments were formalin-fixed or placed into cryotubes and stored under liquid nitrogen for subsequent immunohistochemistry (IHC) or RT-PCR, respectively. Tumor size was evaluated three times per week by caliper measurements and calculated using the following formula: tumor volume = \((\text{length} \times \text{width}^2)/2\). All animal procedures were approved by IACUC at Rhode Island Hospital.

**Establishment of F2 through F7 PDX murine models**

When reached approximately 500 \text{mm}^3 in volume, F1 tumors were excised, washed, diced into several fragments (each fragment with an estimated volume of \(5 \times 5 \times 5 \text{mm}^3\)), and transplanted into 5- to 6-week-old female NSG mice under anesthesia as described for F1 generation mice, and subsequently serially passaged to the F7 generation. Necropsy was performed when the tumors reached approximately 800–900 \text{mm}^3 in volume. The PDX derived tumors, liver and lymph nodes were fixed for routine histology and IHC, and the lungs were placed in Bouin’s solution (HT10132; Sigma-Aldrich, St. Louis, MO) to determine macro-/micro-metastases.

**Antitumor effects of a small molecule inhibitor in vivo**

Potential antitumor effects of a small molecule inhibitor [6] on PDAC were analyzed in F5 generation PDX mice. When tumors reached 100 \text{mm}^3 (4–5 weeks after transplantation), mice were randomized into the experimental or control group to be administered with MO-I-1182 or DMSO, respectively. MO-I-1182 (10 mg/kg) was prepared in DMSO and administered by intraperitoneal (IP) injection daily. The oral formulated MO-I-1182 was prepared in capsules at a concentration of 10 mg/kg and administered orally through the esophagus with an injection syringe. At 5 weeks after the initiation of treatment, mice were sacrificed to assess the antitumor effects of i.p. or oral formulated MO-I-1182. Necropsy was performed and primary tumors, lungs, liver, and lymph nodes were surgically removed. The lungs were immersed in Bouin’s solution, and metastatic nodules were counted by visual observation.

**Total RNA extraction and cDNA synthesis**

Total RNA was extracted from pancreatic tumor tissue using Trizol reagent (Invitrogen) and then purified with RNeasy mini-spin column (Qiagen). Total RNA (1 \text{μg}) of each tumor sample was applied for cDNA synthesis with iScript kit (Bio-Rad) according to the manufacturer’s protocol.

**qRT-PCR**

To evaluate a panel of gene expression in pancreatic tumor tissue, synthesized cDNA from prior step was used as a template for qRT-PCR. The assay was performed with gene specific primer sets and a QuantiTect® SYBR® Green PCR kit (Qiagen) on a StepOnePlus Real-Time PCR System (Applied Biosystems). The cycling conditions were as follows: 95 °C for 15 min, then 40 cycles of 94 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s. Either housekeeping gene GAPDH or β-Actin served as an internal control and the relative mRNA expression was analyzed using 2\(^{-\Delta\DeltaCT}\) method.

**Expression profile of ASPH network components on human tissue microarray**

**Patient sample collection**

The study was approved by the Ethics Committee of IRB at The First Affiliated Hospital of Harbin Medical University, China. All procedures were conducted according to the regulations and guidelines approved by IRB. To quantify ASPH network components in resected tumors from pancreaticoduodenectomy on stage I/II PDAC patients, 166 specimens were randomly selected from banked de-identified tissues without restriction on age, gender, or ethnicity. The tissue bank contains immediately available formalin-fixed paraffin-embedded (FFPE) blocks from PDAC patients as well as complete demographic and clinical characteristics to evaluate the value of ASPH network components expression profiling as a predictor for prognosis.

**Immunohistochemistry (IHC)**

Immunohistochemical staining was conducted on 4-μm FFPE unstained sections using primary antibodies for ASPH (FB50, homemade, 1:10,000), MMP1 (ab38929, 1:1000), and MMP14 (ab3644, 1:1000) from Abcam; SRC Y416/418 (PAB25310, 1:100) from Abnova; ADAM12 (14139-1-AP, 1:100) from Proteinteich; and reagents from Vector Laboratories (CA, USA). The tissue sections and slides were deparaffinized in xylene and rehydrated in a descending ethanol gradient. Antigen retrieval was performed using citric acid-based antigen unmasking solution in a microwave pressure cooker (Nordic Ware, Minneapolis, MN, USA) for 90 s at full power, followed by cool down for 30 min. Endogenous peroxidase activity was quenched with 3% \(\text{H}_2\text{O}_2\) dissolved in methanol for 30 min. The remaining steps of the staining procedure, including tissue blocking, secondary antibody incubation, and ABC reagent incubation, were performed using VECTASTAIN Elite ABC kit (PK-6101, PK-6102).
according to the manufacturer’s instructions. Primary antibodies were diluted in PBS with goat or horse serum attached to ABC kit and were incubated at 4°C overnight. Color development was performed using a DAB Peroxidase (HRP) substrate kit (SK-4100) as per manufacturer’s instructions. Sections were dehydrated using a reversed ethanol gradient followed by xylene and mounted with Mount-Quick (04970-AB, DAIKO Sango, Tokyo, Japan). Staining intensity and distribution of IHC were assessed by two senior pathologists in a blinded manner at The First Affiliated Hospital of Harbin Medical University. Staining intensity and distribution of IHC were assessed by two senior pathologists. Grade = 0 if intensity = absent, distribution = 0; Grade = 1 if intensity = weak, distribution = 1–25%; Grade = 2 if intensity = moderate, distribution = 26–50%; Grade = 3 if intensity = strong, distribution = 51–75%; Grade = 4 if intensity = very strong, distribution = 75–100%. Cumulative score = staining intensity × staining distribution.

Statistical analysis
Statistical analyses were performed with SPSS (version 16, IBM) and GraphPad software packages. Nonparametric data (invadopodia) were analyzed with Kruskal-Wallis one-way ANOVA, followed by Tamhane’s post hoc test. Data with normal distributions were represented by mean ± SD and analyzed using one-way ANOVA followed by Bonferroni post hoc. Spearman’s rank correlation coefficient (ρ) and Pearson’s correlation coefficient (r) were used to quantify the relationship of ASPH expression with other component levels in tumor tissue by IHC. The overall survival (OS) time was calculated from the date of diagnosis to the date of death or last follow-up. Median survival time was estimated using Kaplan-Meier method. Difference in median survival time was examined with log-rank test. Univariate explanatory variables and multivariate Cox proportional hazards regression models were applied to evaluate individual and combined contribution of ASPH network components on OS, adjusting for clinical factors. A p < 0.05 (two-tailed) was considered statistically significant.

Results
ASPH phenocopies aggressively pathological behaviors, depending on β-hydroxylase activity
Expression profile of ASPH in human pancreatic cancer cell lines has been evaluated previously [12]. The MIA-Paca2 (with a low endogenous level) cell lines stably over-expressing empty vector vs. ASPH were generated using the lentivirus expression system [12]. ASPH was stably knocked out (KO) in AsPC-1 and HPAFII cells (with high endogenous levels) by CRISPR-CAS9 system. Since ASPH’s function depends on β-hydroxylase activity [12], candidate compounds potentially against enzymatic activity of ASPH were developed and screened for bioactivity (Additional file 1: Figure S1A). MO-I-1182 (as the third-generation small molecule inhibitor) has demonstrated a dose-dependent effect on cell viability, which is more potent than the first- (e.g., MO-I-1100) or second-generation (e.g., MO-I-1151) small molecule inhibitors as previously characterized [12].

To demonstrate if inhibiting enzymatic activity of ASPH could reverse malignant phenotype of pancreatic cancer cells, serial assays including migration, 2-D invasion, 3D invasion, pancreatosphere formation, and immunofluorescence were performed. In MIA-Paca2, exogenous ASPH substantially spurred migration/2-D invasion (Additional file 1: Figure S1B-C) and epithelial–mesenchymal transition (EMT) as highlighted by downregulated epithelial marker E-cadherin and/or upregulated mesenchymal marker Vimentin (Additional file 1: Figure S1H-I); 3D invasion (Fig. 1a, b), ECM degradation/remodeling (Fig. 1c), and stemness (Fig. 1d; Additional file 2: Figure S2A) as demonstrated by upregulated cancer stem cell markers (CD44 and EpCAM) and/or enhanced pancreatosphere formation. These phenotypes were specifically dismantled by the small molecule inhibitor. Consistently, endogenous ASPH propagated migration/2D invasion (Additional file 1: Figure S1D-G), EMT (Additional file 1: Figure S1J-L), 3D invasion (Additional file 1: Figure S1M), ECM degradation/remodeling (Additional file 1: Figure S1N-O), and stemness (Additional file 2: Figure S2B-I), which were substantially mitigated by the small molecule inhibitor or ASPH KO in AsPC-1 and HPAFII.

To characterize ASPH’s pro-oncogenic properties, in vitro metastasis assay was developed (Fig. 1e). This assay mimics how pancreatic cancer cells invade through the basement membrane at the primary site, subsequently intravasate into/extravasate out of the vasculature system, and consequently form metastatic colonization/outgrowth at distant sites. The ASPH significantly boosted transendothelial migration, subsequent extravasation, and consequent metastatic colonization/outgrowth (pancreatosphere formation) of MIA-Paca2 compared to the empty vector, which were inhibited by MO-I-1182 (Fig. 1f, g). Endogenous ASPH-mediated in vitro metastasis was abolished by MO-I-1182 or ASPH KO in AsPC-1 (Additional file 2: Figure S2J-K).

ASPH physically interacts with ADAM12/15 to activate SRC cascade
Signaling pathways that act as downstream effectors of ASPH activity in pancreatic tumorigenesis are yet to be clarified. Based on bioinformatics, protein–protein interactions between ASPH and serial potential candidates were comprehensively screened. The ADAMs family members are critically involved in tumor pathogenesis. Accordingly, direct physical interactions of ASPH with
**Fig. 1**

In Vitro Metastasis Assay (mimics Intravasation/Extravasation + Invade into distant tissue + Metastatic Colonization in distant site)

**A**
- STEPS:
  - Resuspend cells in Spheroid Formation ECR; add to 96-well Spheroid Formation Plugs
  - Cells assemble into compact spheroids: 3 days
  - Add Invasion Matrix and medium containing invasion modulating compounds: 1-2 hours
  - Cells invade into the surrounding matrix in response to invasion modulating compounds: 3-6 days
  - Total: 4-9 days

**B**
- MIA PaCa2
  - MO-I-1182 (50nM)
  - Vector
  - ASPH

**C**
- Phalloidin & DAPI
- Velocity

**D**
- MO-I-1182 (50nM)
- Vector
- ASPH
- MIA PaCa2
- Relative Colony Size

**E**
- In Vitro Metastasis Assay (mimics Intravasation/Extravasation + Invade into distant tissue + Metastatic Colonization in distant site)

**F**
- MO-I-1182 (50nM)
- Vector/GFP
- ASPH/ASPH/GFP
- MIA PaCa2
- Relative Extravasation

**G**
- MO-I-1182 (50nM)
- Vector/GFP
- ASPH/GFP
- MIA PaCa2
- Relative Colony Number

*Fig. 1* (See legend on next page)
ADAM12 and ADAM15 were identified by co-IP and Western blot (Fig. 2a). ADAM12 or ADAM15 interacts with SH3 domain of SRC [13–15], resulting in activation of the SRC cascade in pancreatic cancer cells (Fig. 2b). A high level of endogenous ASPH activated SRC (phosphorylated Y416), which was inhibited by Dasatinib (SRC inhibitor) in HPAFII. ADAM12/ADAM15 overexpression strengthened activation of SRC, which was blocked by Dasatinib (Fig. 2b). The ASPH KO, ADAM12, or ADAM15 knock-down (KD) prevented SRC from being activated in HPAFII (Fig. 2c). We hypothesized ASPH acts as an activator of SRC signaling to promote tumor progression in pancreatic cancer. Indeed, ASPH upregulated active form of SRC, which was impeded by both MO-I-1182 and Dasatinib (Fig. 2d, e). Then, we determined if inhibition of SRC activity can lessen ASPH-mediated pro-oncogenic properties. Notably, ASPH enhanced migration/invasion (Additional file 3: Figure S3B-C), 3-D invasion (Fig. 2h), ECM degradation/remodeling (Fig. 2i), stemness (Fig. 2j), and in vitro metastasis (Fig. 2k-l) were substantially diminished by Dasatinib in MIA-Paca2. Endogenous ASPH-induced SRC activation (Fig. 2f; g; Additional file 3: Figure S3A), migration/invasion (Additional file 3: Figure S3D-G), 3-D invasion (Additional file 3: Figure S3H), ECM degradation/remodeling (Additional file 3: Figure S3I-J), stemness (Additional file 3: Figure S3K-L), in vitro metastasis (Additional file 3: Figure S3M-N) were undermined by Dasatinib in AsPC-1 and HPAFII. Collectively, ASPH activated the SRC signaling pathway to generate and maintain malignant phenotypes in pancreatic cancer.

ASPH-mediated aggressive malignant phenotypes stem from invadopodia-driven degrading/remodeling ECM

SRC signaling pathway is critical for invadopodia formation, maturation, and function [16]. Thus, we hypothesized the ASPH-SRC axis integrates invadopodia machinery to drive metastasis of pancreatic cancer cells. It has been reported that N-WASP enables MMP14 trafficking into invadopodia, provides the correct cytoskeletal framework to couple matrix remodeling with invadopodia [17], and assembles actin polymerization at invadopodia sites [18]. Then, could inhibition of N-WASP activity diminish ASPH-mediated pro-oncogenic properties? Exogenous ASPH enhanced malignant phenotypes, including migration/invasion (Additional file 4: Figure S4A), invadopodia formation-ECM degradation/remodeling (Fig. 3a), 3-D invasion (Fig. 3b), stemness (Fig. 3c), and in vitro metastasis (Fig. 3d, e), were disassembled by N-WASP inhibitor Wiskostatin in MIA-Paca2. Endogenous ASPH-induced migration/invasion (Additional file 4: Figure S4B-C), invadopodia formation-ECM degradation/remodeling (Additional file 4: Figure S4D-E), 3-D invasion (Additional file 4: Figure S4F), stemness (Additional file 4: Figure S4G-H), and in vitro metastasis (Additional file 4: Figure S4I-J) were deconstructed by Wiskostatin in AsPC-1 and HPAFII.

ASPH promotes pancreatic cancer metastasis in vivo

Can ASPH-mediated pro-oncogenic properties be reversed/blacked by small molecule inhibitors in vivo? We explored the effects of MO-I-1182 on primary tumor growth and metastasis using a PDX (patient-derived xenograft) murine model of human PDAC. The demographic and pathologic characteristics of selected patients with PDAC are detailed in Additional file 7: Table S1. Three representative PDX tumors from F0 generation mice derived from three PDAC patients were serially propagated from F1 to F7 generation. Case #3 (patient B) had spontaneously developed pulmonary metastasis during disease progression whereas Case #1 (patient A) and Case #6 (patient C) were free from clinically detectable metastatic diseases (Additional file 7: Table S1). The histologic characteristics of the original PDAC tumors were compared with F1–F4 generation mice (Fig. 4a, b; Additional file 5: Figure S5A-B). The original histologic architecture was bona fide preserved in the PDX mice, where the transformed glandular epithelium was partially enclosed by a dense desmoplastic stroma. Glandular cellularity was gradually increased in the PDX following serial passage in the NSG mice. ASPH expression profiling in the original tumor derived from PDAC patients was continuously recapitulated following serial passages for over 56 weeks (Additional file 5: Figure S5C). Patient B with clinical pulmonary metastasis transmitted this phenotype faithfully to a subsequent PDX model from F1 to F7 generation mice (Fig. 4a; Additional file 5: Figure S5D-E). One hundred percent of PDX mice spontaneously developed macro-/micro-pulmonary metastases. ASPH expression was authenticated maintained in the macro-/micro-pulmonary metastases (Fig. 4a–d). No pulmonary metastasis was observed.
in the PDX F1 to F7 generation mice derived from patients A and C.

Small molecule inhibitor targeting ASPH inhibits primary tumor growth and pulmonary metastasis

To evaluate if ASPH activates SRC cascade in vivo, expression profiling of ASPH network was measured in the F4 to F7 generation PDX tumors derived from Case #3 (patient B) with transmissible spontaneous pulmonary metastasis, patients A and C without detectable metastasis. All three patients exhibited ASPH-positive PDX tumors through F4 to F7 generation. Only patient B displayed markedly activated SRC (pSRC Y416/418), upregulation of regulator ADAM12, and downstream MMPs...
Fig. 3 ASPH-SRC signal promotes invadopodia formation, maturation, and function in pancreatic cancer. 

- Invadopodia formation and ECM degradation/remodeling in response to Wiskostatin.
- 3-D tumor spheroid invasion in response to Wiskostatin.
- 3-D pancreatosphere formation in response to Wiskostatin.
- Transendothelial migration and extravasation.
- Invasion through basement membrane and subsequent pancreatosphere formation in response to Wiskostatin. *p < 0.05; **p < 0.01; ***p < 0.001

Fig. 4 In vivo antitumor effects of a third-generation SMI (MO-I-1182) targeting ASPH enzymatic activity on PDX murine models of human PDAC.

- Histopathologic characteristics (H&E) of original tumors (F0) derived from PDAC patient B and xenografted tumors in representative mice of F1 through F4 generation PDX model.
- Pulmonary macro-metastases in representative F4 PDX mice derived from patient B. One hundred percent (14/14) of F4 PDX mice had spontaneously developed pulmonary metastasis.
- Expression profiling of ASPH in resected primary PDAC tumor specimens derived from patients B.
- Gross appearance of the involved lungs, histopathologic characteristics, and expression profiling of ASPH in transplanted primary tumors as well as pulmonary macro-metastases in a representative mouse of the F5 generation PDX model derived from PDAC patient B.
- Transplanted primary tumor growth in mice of the F5 generation PDX model in response to i.p. injected SMI vs. DMSO control. It took 4–5 weeks for the transplanted tumors to grow up to 100 mm³, when treatment with MO-I-1182 (10 mg/kg, i.p., every other day) was initiated. The mice were followed up for 5 weeks until the tumors grew up to 1000 mm³.
- Antitumor effects of i.p. injected SMI on pulmonary metastasis. SMI blocks pulmonary micro-/macro-metastases in mice of F5 generation PDX derived from patient B.
- Expression profiling of ASPH and MMPs detected by IHC and qRT-PCR in representative mice of the F5 generation PDX model treated with SMI vs. DMSO control. *p < 0.05; **p < 0.01; ***p < 0.001
(Fig. 4c). Patient B had the highest level of ASPH expression (in terms of immunostaining intensity [strong] and distribution [75–100%]) compared to patient A or C. Importantly, all the components in the ADAM12-SRC-MMPs axis were activated in patient B, but not in patient A or C. Tumor development/progression were accelerated with serial passage in the PDX model (Additional file 5: Figure S5F). The spontaneous pulmonary metastasis is proposed to be attributable to activation of SRC cascades in the primary PDX tumor. A SMI specifically targeting ASPH enzymatic activity exerted antitumor effects on PDAC growth and progression in vivo. F5 to F7 generation PDX tumors derived from patient B were allowed to grow subcutaneously for 4–5 weeks on the back of NSG mice. MO-I-1182 was administered i.p. daily for another 5 weeks. Primary PDX tumor growth (on the back) was monitored weekly. The animals were sacrificed 5 weeks later and the lungs examined for metastases. Primary PDAC tumor growth and pulmonary metastases were substantially inhibited with i.p. formulation MO-I-1182 preparation (Fig. 4e, f). SRC signaling components were consistently downregulated in response to ASPH enzymatic inhibition (Fig. 4g–i). Therefore, the small molecule inhibitor efficiently blocks PDAC development, progression, and metastatic spread to the lung.

Expression profiling of the ASPH-SRC axis predicts clinical outcome of PDAC

To confirm ASPH-SRC axis functions in PDAC patients, IHC was conducted to illustrate differential expression between tumor and adjacent non-malignant pancreatic tissue. The demographic/clinical features of the study population (N = 166) are summarized in Additional file 7: Table S2. The ASPH was detected in 97.6% of PDAC patients, with a negative, low, moderate, high, or very high expression rate of 2.4%, 22.9%, 23.5%, 27.7%, and 23.5%, respectively (Additional file 6: Figure S6A). ASPH was undetectable in adult normal pancreas (Fig. 5a), inflammatory diseases (acute/chronic pancreatitis), or pancreatic neuroendocrine tumor [12]. ASPH was upregulated at early stage preinvasive pancreatic neoplasm including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN) (Fig. 5b), whereas it was markedly expressed in mucinous cystadenocarcinoma (MCAC) (Fig. 5c), invasively advanced/spontaneously metastatic pancreatic cancer (Fig. 5d), and extremely aggressive undifferentiated pancreatic carcinoma with osteoclast-like giant cells (UC-OGC) (Fig. 5e), compared to adjacent non-malignant pancreas (Fig. 5f).

SRC network components were consistently downregulated or upregulated in ASPH negative vs. positive PDAC patients. ASPH was moderately (very) strongly expressed in poorly differentiated more aggressively tumors, whereas it was negatively weakly expressed in moderately well differentiated less-invasive tumors (Fig. 5d, g, h; Additional file 6: Figure S6B–F). ADAM12-SRC signaling was activated in PDAC patients, where ASPH expression positively correlated with ADAM12 and active SRC (Fig. 6a–d). ADAM12 expression positively correlated with active SRC (Fig. 6e).

To explore if ASPH network level predicts clinical outcome of PDAC patients, Kaplan-Meier plot and Cox proportional hazards regression model were employed. Compared to a negative-low level, a moderate–very high level of ASPH, ADAM12, activated SRC, and MMPs correlated with curtailed overall survival (OS) of pancreatic cancer patients (log-rank test, p < 0.001) (Fig. 6f–j).

Do ASPH network elements act synergistically on modulating clinical outcome of PDAC patients? A potential joint effect of individual molecules on OS was analyzed by combing the unfavorable expression scores significantly associated with reduced survival in the multivariate models. Increased numbers/expression levels of unfavorable molecules conferred reduced OS (Fig. 6k, l; Additional file 7: Table S3–4). Patients with 0–2 (n = 4), 3–5 (n = 8), 6–8 (n = 24), 9–12 (n = 73) of unfavorable expression scores of the five molecules had median survival time of 55.4, 15.9, 9.7, and 5.0 months, respectively (p < 0.001). Compared to patients with 0–2 unfavorable score, for those carrying 3–5, 6–8, or 9–12 unfavorable scores, adjusted hazard ratio (HR) (95% confidence interval) was 2.91 (0.59–14.40), 5.24 (1.22–22.49), 11.14 (2.60–47.81), and 18.30 (4.08–82.14), respectively (p < 0.001).

Discussion

ASPH promotes pancreatic cancer progression through activating the SRC signaling pathway. The ASPH-SRC axis guides tumor cells to strengthen invadopodia formation/maturation and ECM degradation/remodeling, migration, invasion, stemness, transendothelial migration (intravasation/extravasation), and metastatic colonization/outgrowth at distant sites (e.g., lungs). In a dose-/intensity-dependent pattern, ASPH, active SRC, ADAM12, and MMPs independently and synergistically confer adverse prognosis of PDAC patients. Patient’s OS was curtailed with an increase in numbers/expression levels of unfavorable molecules. The ASPH-SRC axis components are proposed to be novel prognostic factors for PDAC.

ASPH mediates invadopodia formation/maturation/function, as described by enhanced degradation/remodeling of ECM and altered morphology in 3-D culture. As shown in Fig. 3d, N-WASP inhibitor Wiskostatin could not completely abolish the ASPH-mediated extravasation and invadopodia formation. Thus, ASPH could
Fig. 5 (See legend on next page.)
simultaneously depend on complex molecular mechanisms to maintain malignant phenotypes besides the N-WASP signal, which requires further investigation.

ASPH activates SRC through directly interacting with ADAM12/ADAM15, which activates SRC [13–15]. SRC in turn enhances ADAM enzymatic activity [19–21] and forms a positive feedback loop. SRC pathway promotes angiogenesis, invadopodia formation [18, 22], and metastasis [23, 24]. Proteinase MMPs upregulated by the SRC signaling and ADAMs stabilized by ASPH are essential components for invadopodia architecture [18]. MMPs act as outlets of SRC cascade and direct executors for ECM degradation/remodeling to facilitate invasion and metastasis of pancreatic cancer cells.

The third-generation SMI will inhibit about 90–95% of ASPH’s enzymatic activity. Under this circumstance, ASPH’s enzymatic activity still remains at 5–10%. Therefore, MO-I-1182 does not abolish completely ASPH-mediated phenotypes.

It is challenging to develop and evaluate drugs targeting metastasis due to lack of suitable animal models that realistically mimics human tumor histopathology. We have established a novel PDX model of human PDAC that spontaneously metastasizes to murine lungs from a subcutaneous grown neoplasm on the back of NSG mice. This phenotype faithfully recapitulated histopathological/clinical characteristics of original tumor derived from specific patient and was serially propagated in 100% of the animals from the F2 to F7 generation, thus far. Therefore, ASPH is a potential driver of pulmonary metastasis where SRC signaling pathways are critically involved. ASPH activates SRC cascade in the primary PDAC tumor, upregulates downstream target genes (e.g., MMPs), and contributes to multiple steps of pancreatic cancer progression.

![Fig. 5](image1)

**Fig. 5** Expression profiling of ASPH network components in pancreatic cancer patients. a–f Expression of ASPH in a normal pancreas, b precursor lesions for sporadic pancreatic cancer: PanINs, IPMN, and MCN; c pancreatic MCAC, d invasive PDAC, e OGCs; f adjacent non-malignant pancreas. g, h Histopathologic characteristics and ASPH network expression profiling in two representative tumors derived from PDAC patients. SRC cascades were consistently g downregulated/silenced vs. h upregulated/activated in ASPH negative (patient #12) vs. positive (patient #13) PDAC.

![Fig. 6](image2)

**Fig. 6** Expression levels of ASPH-Notch/SRC axis elements predict clinical outcome of PDAC patients. a–e ASPH expression level positively correlated with SRC components levels. Active SRC expression level positively correlated with ADAM12 level. Staining intensity and distribution of IHC were evaluated under ×10, ×40, ×100, and ×400 magnification. The average of percentage (number of positive staining cells/100 tumor cells) was calculated from at least 10 areas per high power field (HPF). f–j Compared to a negative-low level, a moderate-high level of ASPH; MMP1/14; ADAM12; or active SRC expression conferred reduced OS of PDAC patients (log-rank test, *p* < 0.001). k, l Combined effects of four (SRC axis) or five (ASPH-SRC axis) molecules on OS of PDAC patients using the Kaplan-Meier method. The numbers from 0 to 12 indicate the total expression scores of at-risk proteins (log-rank test, **p** < 0.001). *p* < 0.05; **p** < 0.01; ***p*** < 0.001.
cancer metastasis. Specific third-generation small molecule inhibitor targeting ASPH enzymatic activity substantially disrupted primary tumor growth and impeded pulmonary metastasis.

Metastasis is a complicated multi-step cascade conferring the deadly destination of cancer. Tumor cells disseminate from the primary site, intravasate into the vascular/lymphatic system, survive in circulation, extravasate across the endothelium, and eventually colonize secondary sites. However, how cancer cells intravasate/extravasate is yet to be illustrated. Invadopodia are cancer-specific protrusive and adhesive structures on the basolateral side of cultured cancer cells. However, physiological roles for invadopodia in cancer have not been established. Invadopodia concentrate proteases (MT1-MMP, MMP1) and Tks5 for local directed release and enzymatic activity for ECM degradation and remodeling [25, 26].

In randomly selected PDAC patients, expression levels of ASPH-SRC components independently predict prognosis of PDAC. The more harmful molecules patients harbor, the more deleterious clinical outcome is destined. In adult normal pancreas, ASPH is silenced, in sharp contrast to be turned on during malignant transformation. ASPH is upregulated from pre-malignant pancreatic lesions (PanINs, MCN, and IPMN), substantially enhanced in MCAC, advanced/spontaneously metastatic pancreatic cancer, and extremely aggressive UC-OGC. SRC signaling elements were consistently downregulated or upregulated in ASPH negative vs. positive PDAC patients. Individual components of the ASPH-SRC axis vigorously and synergistically contribute to worse prognosis, dose- and intensity-dependently. More importantly, we have illustrated that ASPH can be measured by ELISA using patients’ serum samples. In this immunoassay, ASPH is detectable/significantly increased in cancer patients but undetectable or very tiny, if any, in health control donors. Therefore, ASPH is promising to serve as a biomarker for early diagnostics and prognostics of pancreatic cancer.

Limitations of this study include the following: (a) within ADAM12 or ADAM15, specific interaction/binding sites for and hydroxylation sites by ASPH have yet to be disclosed. Furthermore, upon hydroxylation by ASPH, dynamic configurational or functional changes of ADAM12/ADAM15 have yet to be explored. Whether this hydroxylation will be required for maintenance of SRC signal activation is under investigation. (b) To decipher prognostic values of ASPH network, a single-center-based retrospective study was designed, which may cause sampling bias. In addition, a limited number of proteins were investigated, and potential false-positive findings might be resulted from multiple comparisons [27, 28].

Conclusions

Extensive efforts to characterize ASPH have revealed its key roles in multi-steps of pancreatic cancer metastasis: EMT, ECM degradation/remodeling, invasion through the basement membrane at the primary site, intravasation, survival in circulation, extravasation, and eventually metastatic colonization/outgrowth. Newly developed small molecule inhibitor bind to highly conserved catalytic site of ASPH, leading to substantial reduction in β-hydroxylase activity [6, 12, 29–31], abrogate downstream oncogenic events induced by the SRC signaling pathway. Therefore, the ASPH-SRC axis-mediated pro-invasive invadopodia are collapsed following treatment and ASPH’s pro-metastatic properties are diminished in pancreatic cancer. Our study has provided direct evidence of functional roles for invadopodia during pancreatic cancer cell intravasation/extravasation and consequent distant metastasis, which has revealed an opportunity for optimal intervention in this clinically important process. This study together with previous findings [8, 9, 12, 30–40] establishes ASPH as a therapeutic target for pancreatic cancer. Importantly, we have demonstrated a paramount role of the ASPH-SRC axis in determining clinical outcome of patients with pancreatic cancer.

Supplementary information

The online version of this article (https://doi.org/10.1186/s13045-019-0837-z) contains supplementary material, which is available to authorized users.

Additional file 1: Figure S1. ASPH mediated migration, invasion, EMT and ECM degradation/remodeling are reversed in vitro by a small molecule inhibitor (SMI) specifically against β-hydroxylase activity in PC. (A) Structure of candidate 3rd generation SMI s targeting ASPH enzymatic activity. (B-G) Migration/invasion index of (B-C) MIA Paca2 (expressing empty vector and ASPH, respectively); (D-E) AsPC-1 and (F-G) HPAFII (expressing CRISPR vector and ASPH KO, respectively) in response to SMI. (H-L) Expression of mesenchymal marker Vimentin (H-J) or epithelial marker E-cadherin (K-L) in response to SMI. (M) 3-D tumor spheroid invasion of AsPC-1 cells in response to SMI. (N-O) ECM degradation/remodeling of AsPC-1 and HPAsfII cells in response to SMI. p <0.001; **p<0.01; ***p<0.001.

Additional file 2: Figure S2. ASPH mediated cancer stemness are reversed in vitro by SMI specifically against β-hydroxylase activity in PC. (A) Expression of cancer stem cell marker CD44 in MIA Paca2 cells in response to SMI. (B) Expression of mesenchymal marker Vimentin or cancer stem cell marker CD44 in AsPC1 cells in response to SMI. (C-D) Expression of cancer stem cell marker EpCAM in AsPC1 cells in response to SMI. (E) Expression of cancer stem cell marker CD44 in AsPC1 cells in response to SMI. (F-G) Expression of cancer stem cell markers CD44 and EpCAM in HPAsfII cells in response to SMI. (H-I) 3D pancreatic spheroid formation of AsPC-1 and HPAsfII cells in response to SMI. (J) Transendothelial migration and invasion/extravasation; (K) Invasion through basement membrane and subsequent pancreatic spheroid formation of AsPC-1 cells in response to SMI. p<0.05; **p<0.001; ***p<0.001.

Additional file 3: Figure S3. ASPH activates SRC signaling pathways in PC. (A) ASPH enhanced activation of SRC signaling pathway in HPAsfII cells, which was inhibited by both SMI and Dasatinib, but not DAPT. (B-G) Migration and Invasion index of MIA PaCa2, AsPC-1 or HPAsfII cells in response to Dasatinib. (H) 3D tumor spheroid invasion of AsPC-1 cells in response to Dasatinib. (I-J) ECM degradation/remodeling in AsPC-1 and HPAsfII cells in response to Dasatinib. (K-L) 3D Pancreatic spheroid formation...
of AsPC-1 and HPAFII cells in response to Dasatinib. (II) Transendothelial migration and invasion/remodeling in AsPC-1 cells in response to Wiskostatin. (I) Migration/Invasion index of PC cells in response to Wiskostatin. (D-E) Invadopodia formation and ECM degradation/remodeling in AsPC-1 and HPAFII cells in response to Wiskostatin. (F) 3D tumor spheroid invasion of AsPC-1 cells in response to Wiskostatin. (G-H) 3D pancreatosphere formation of AsPC-1 and HPAFII cells in response to Wiskostatin. (I) Transendothelial migration and extravasation. (J) Invasion through basement membrane and subsequent pancreatosphere formation of AsPC-1 cells in response to Wiskostatin. 

Additional file 4: Figure S4. ASPH-SRC axis mediated aggressiveness of malignant phenotypes in PC, which are significantly attenuated in vitro by N-WASP inhibitor Wiskostatin. (A-C) Migration/Invasion index of PC cells in response to Wiskostatin. (D-E) Invadopodia formation and ECM degradation/remodeling in AsPC-1 and HPAFII cells in response to Wiskostatin. (F) 3D tumor spheroid invasion of AsPC-1 cells in response to Wiskostatin. (G-H) 3D pancreatosphere formation of AsPC-1 and HPAFII cells in response to Wiskostatin. (I) Transendothelial migration and extravasation. (J) Invasion through basement membrane and subsequent pancreatosphere formation of AsPC-1 cells in response to Wiskostatin. p<0.05; p<0.01; **p<0.001.

Additional file 5: Figure S5. In vivo antitumor effects of SM2 on PDAC PDX models. Expression profiling of ASPH network components in pancreatic cancer patients. (A) Expression profiling of ASPH in 6 surgically resected PAD tumors (Additional file 7: Table S3) as candidates for transplantation into the NSG mice for establishment of PDX models. Tumor specimens from Case1, #2, #3, #6 were serially passaged to NSG mice. (B) Expression profiling of ASPH in original PDAC tumors from 3 representative patients (Patient A, Case1; B, Case #3; C, Case #6) and a transplanted tumor in a representative mouse of F4 generation PDX model derived from Patient B. (C) Tumor growth in a representative F0 PDX mice derived from Patient A. (D) Pulmonary macro- micro-metastases of a representative F2 PDX mouse derived from Patient B. (E) Gross appearance of the involved lungs, histopathological characteristics (H&E) and expression profiling of ASPH in transplanted primary tumors as well as pulmonary macro-metastases in a representative mouse of F5 generation PDX model derived from PDAC Patient B. (F) Tumor development was accelerated with generation in PDX mice. p<0.05; p<0.01; **p<0.001.

Additional file 6: Figure S6. Expression profiling of ASPH network components in PC patients. (A) A summary of ASPH immunoreactivity in tumorous tissue (compare to adjacent nonmalignant) derived from PDAC patients (N=166). (B) In primary tumor derived from a PDAC patient, SRC signaling pathway was inactive despite of a negative-low expression of ASPH due to lack of SRC expression. (C-F) Histopathological characteristics (H&E) and ASPH network components expression profiling of representative tumors derived from 4 PDAC patients. Consistent downregulation vs. upregulation of activated SRC (phosphorylated at Tyr416); ADAM12; MMP1; and MMP14 based on negative-low vs. moderate-high levels ASPH, compared to adjacent non-malignant pancreas tissues (P<0.001, 2-sided paired t test).

Additional file 7: Table S1. Demographic/clinical characteristics of patients and histopathological classification of PDAC tumors transplanted into the PDX model of NGS mice. Table S2 Patients’ Characteristics (N=166). Table S3 Clinical Predictors for Overall Survival (N=166).

Abbreviations
2-D: Two-dimensional; 3-D: Three-dimensional; ADAM: A Disintegrin and Metalloprotease Domain; ASPH: Aspartate β-hydroxylase; BSA: Bovine serum albumin; DLL: Delta-like; ECD: Extracellular domain; ECM: Extracellular matrix; EGF: Epidermal growth factor; EMT: Epithelial–mesenchymal transition; ERK: Extracellular signal-regulated kinase; FBS: Fetal bovine serum; FFPE: Formalin-fixed paraffin embedded; H&E: Hematoxylin and eosin; HCC: Hepatocellular carcinoma; HR: Hazard ratio; HUVEC: Human umbilical vein/vascular endothelium; I.P.: Intraperitoneal; IACUC: Institutional Animal Care and Use Committee; IHC: Immunohistochemistry; IPMN: Intraductal papillary mucinous neoplasm; KO: Knockout; MAPK: Mitogen-activated protein kinase; MCAC: Mucinous cystadenocarcinoma; MCN: Mucinous cystic neoplasm; MMP: Matrix metalloproteinase; NSG: NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; NOD-iscd Il2rgnull; N-WASP: Neural Wiskott-Aldrich syndrome protein; OS: Overall survival; PanIN: Pancreatic intraepithelial neoplasia; PDAC: Pancreatic ductal adenocarcinoma; PDX: Patient-derived xenograft; UC-OGC: Undifferentiated pancreatic carcinoma with osteoclast-like giant cells.

Acknowledgements
We highly appreciate Dr. Mark Olsen at the Department of Pharmaceutical Sciences, College of Pharmacy--Glendale, Midwestern University, Glendale (Arizona 85308, USA) for synthesizing, structural characterization, and providing data on the purity of these small molecule inhibitors (SMIs) of ASPH (including MO-1-1182 [6, 12]); Laboratory for Molecular Biology and Cytochemistry Research at the University of Oklahoma Health Sciences Center for the use of the Core Facility which provided Mass Spectrometry/Proteomics service; Dr. Iannis Alifantis at NYU School of Medicine for providing with pDNA3 NOTCH1 full-length plasmid.

Funding
This work was supported in part by National Institutes of Health (NIH) grant CA123544, P30GM110759 and Institutional Funds of the United States (to J.R.W and X.Q.D.); National Natural Science Foundation of China (Grant No. 81670583 to B.S).

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to potential comprise of patient’s privacy but are available from the corresponding author on reasonable request.

Author’s contributions
XQD, QSL, JIWW, KO, and BS contributed to the conceptualization; QSL, LL, KO, WC, JXC, ML, XL, and QGX contributed to the methodology; QSL, KO, LL, XWB, XSC, HZ, FLH, KN, RK, HC, SHZ, YWW, and QGX contributed to the investigation; QSL, KO, LL, and QXD contributed to the statistical analysis. QSL, KO, and QXD contributed to the writing of the original draft. J.IW, BS, ML, and QXD contributed to the writing and review and editing. XQD, JIWW, HS, KC, and BS contributed to the resources. XQD, JIWW, and BS are responsible for supervision. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study has been approved by Ethics Committee of Institutional Review Board (IRB) at Rhode Island Hospital/Brown University, USA, and The First Affiliated Hospital of Harbin Medical University, P.R. China. All procedures (involving human data and human tissue) were conducted according to all current ethical regulations and guidelines.

All animal procedures were approved by Institutional Animal Care and Use Committee (IACUC) at Rhode Island Hospital/Brown University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Liver Research Center, Rhode Island Hospital, Warren Alpert Medical School, Brown University, 55 Claverick Street, 4th Fl., Providence, RI 02903, USA.
2Department of Internal Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 731014, USA.
3Department of Pancreatic and Biliary Surgery; Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin 150081, Heilongjiang Province, People’s Republic of China.
4Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang Province, People’s Republic of China.
5Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, People’s Republic of China.
6Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing, People’s Republic of China.
7Institute of Life Sciences, Jiangsu University, Zhenjiang 212013, People’s Republic of China.
8Department of Hepatic Surgery, Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
9Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, The University of Sciences and Technology of China, No. 17 Lujiang Road, Hefei City 230001, An Hui Province, People’s Republic of China.
10Immunoimmunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
11Division of...
Reference:

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018;68(6):394–424.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):17–34.

3. Gundogan F, Elwood G, Greco D, Rubin LP, Pinar H, Carlson RI, et al. Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: relevance to early pregnancy loss. Hum Pathol. 2007;38(11):50–9.

4. Cantarini MC, de la Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44(2):496–507.

5. Wands JR, Kim M. WNT/beta-catenin signaling and hepatocellular carcinoma. Hepatology. 2014;60(2):452–4.

6. Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, Kim M. Upregulation of T-cell factor-4 is a more responsive target genes in hepatocellular carcinoma. Liver Int. 2013;33(7):1100–12.

7. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol. 2006;44(5):971–83.

8. Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, et al. Involvadoppia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014;7:558–70.

9. Artym W, Zhang Y, Seiller-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of contactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006;66(8):3034–43.

10. Dong X, Lin Q, Aihara A, Huang OK, Olsen MJ, Lin Q, Chung W, Tang Q, et al. A cell-surface beta-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60(4):1302–13.

11. Artym W, Zhang Y, Seiller-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of contactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006;66(8):3034–43.

12. Dong X, Lin Q, Aihara A, Lin Q, Huang OK, Chung W, et al. Aspartate beta-hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget. 2015;6:1231–48.

13. Kang Q, Cao Y, Zolkiewska A. Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochem J. 2000;352(Pt 3):883–92.

14. Poghosyan Z, Robbins SM, Houslay MD, Webster A, Murphy G, Edwards DR. Phospholipid-dependent interactions between ADAM15 cytoplasmic domain and Src family protein tyrosine kinases. J Biol Chem. 2002;277(7):4999–5007.

15. Sun C, Wu MH, Guo M, Day ML, Lee ES, Yuan SY. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc Res. 2010;87(2):348–55.

16. Balzer EM, Whipple RA, Thompson K, Boggs AE, Slovik J, Cho EH, et al. C-Src differentially regulates the functions of microtubules and invadopodia. Oncogene. 2010;29(48):6402–8.

17. Yu X, Zech T, McDonald L, Gonzalez EG, Li A, Macpherson J, et al. N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J Cell Biol. 2012;199(3):527–34.

18. Murphy DA, Courtright SA. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12(7):413–26.

19. Stauz D, Sanjay A, Henderson MT, Albrechtsen R, Wewer UM, Kveiborg M. ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates Src kinase activity. Exp Cell Res. 2010;316(1):55–67.

20. Niu A, Wen Y, Liu H, Zhan M, Jin B, Li YP. Src mediates the mechanical activation of myogenesis by activating TNFalpha-converting enzyme. J Cell Sci. 2013;126(19):4349–57.

21. Maretskiy T, Le Gall SM, Woppenberg-Pietrus S, Eder J, Overall CM, Huang XY, et al. Src stimulates fibroblast growth factor-2 shedding by an ADAM15 splice variant linked to breast cancer. Cancer Res. 2009;69(11):4573–6.

22. Paz H, Pathak N, Yang J. Invading one step at a time: the role of invadopodia in tumor metastasis. Oncogene. 2014;33(3):4193–202.

23. Ji H, Greene DW, Bamonte TK, Ltd, Tauro B, Rai A, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13(10–11):1672–86.

24. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesci Mark M, et al. Tumor exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35.

25. Clark ES, Whigham AS, Yardbrough WG, Weaver AM. Contactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007;67(9):4227–35.

26. Magalhaes MA, Larson DR, Madler CC, Bravo-Cordero JJ, Gil-Henn H, Oser M, et al. Contactin phosphorylation regulates cell invasion through a phi-pathway. J Cell Biol. 2011;195(5):903–20.

27. Dong X, Jai L, Li Y, Evans DB, Wang H, Hess KR, et al. Significant associations of mismatch repair gene polymorphisms with clinical outcomes of pancreatic cancer. J Clin Oncol. 2009;27(10):1992–7.

28. Chung OK, Iwagami Y, Aihara A, Huang OK, de la Monte S, Thomas JM, et al. Anti-tumor effects of second generation beta-hydroxylase inhibitors on cholangiocarcinoma development and progression. PLoS One. 2016;11(3):e0150336.

29. Iwagami Y, Huang OK, Olsen MJ, Thomas JM, Jang G, Kim M, et al. Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase beta1 in hepatocellular carcinoma. Hepatology. 2016;63(4):1213–26.

30. Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot A, et al. Aspartate-beta-hydroxylase induces epitho-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33(10):1256–66.

31. Shimoda N, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol. 2012;56(5):1129–35.

32. Noda T, Shimoda M, Ortiz V, Sirica AE, Wands JR. Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology. 2012;55(1):86–97.

33. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of asparaginyl-beta-hydroxylase/PMK expression in invasive ductal carcinoma. J Pathol. 2009;216(2):339–44.

34. Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol. 2007;38(1):17–25.

35. Maeda T, Taguchi K, Aishima S, Shimada M, Hinz D, Larusso N, et al. Clinicopathological correlates of asparaginyl-beta-hydroxylase overexpression in cholangiocarcinoma. Cancer Detect Prev. 2004;28(3):313–8.

36. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoi M, Wands JR, et al. Antisense oligodeoxynucleotides directed against asparaginyl-beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol. 2003;38(5):615–22.

37. Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. Human asparaginyl-beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas. 2002;25(1):39–44.

38. Ince N, de la Monte SM, Wands JR. Overexpression of human asparaginyl-beta-hydroxylase is associated with malignant transformation. Cancer Res. 2006;66(1):1261–6.

39. Lavalaisere L, As S, Nishiyama M, de la Monte S, Stern AM, Wands JR, et al. Overexpression of human asparaginyl-beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest. 1996;98(6):1313–23.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.